Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.

Products, services, technology

Grafalon®, has been used for over 30 years to treat patients. It has approval for use in immunosuppressive therapies for prevention of graft- versus- host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation and in treatment of aplastic anemia.

Facts & figures
  • Type of organization
    Public company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in